DelMar Pharmaceuticals is dedicated to developing innovative cancer therapies, with a primary focus on their lead candidate, VAL-083. This first-in-class small molecule is designed to target DNA, effectively inhibiting cancer cell replication and division, which ultimately leads to cell death. VAL-083 has undergone extensive clinical evaluation, including 42 Phase 1 and Phase 2 trials sponsored by the U.S. National Cancer Institute (NCI). Its unique ability to cross the blood-brain barrier makes it particularly promising for treating central nervous system tumors, such as glioblastoma multiforme (GBM), especially in cases where patients are resistant to existing therapies.

The company employs a strategic approach to drug discovery, leveraging collaborations with academic and clinical research institutions worldwide. DelMar Pharmaceuticals utilizes proprietary bioinformatics tools from Valent Technologies LLC to screen and identify potential drug candidates efficiently. This methodology allows the company to focus on developing compounds with a strong scientific rationale for specific cancer indications, particularly in patients who have not responded to or cannot tolerate current treatments. Their pipeline includes ongoing studies for VAL-083 in various cancer types, including ovarian cancer and pediatric brain tumors, highlighting their commitment to addressing unmet medical needs in oncology.

Canada

VAL-083 is a small-molecule chemotherapeutic that benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer therapy overseas.  Efficacy has been demonstrated in a range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.   Del Mar Pharma has filed an IND with the USFDA to initiate a dose-escalating Phase II clinical trial in refractory GBM, a major market opportunity.

DelMar Pharmaceuticals

Company Details